SKP2, an F-box protein of the SCF type of the E3 ubiquitin ligase complex, plays an
important function in driving tumorigenesis through the destruction of numerous tumor …

BACKGROUND The intervention of advanced prostate cancer (PCa) in patients has been
commonly depending on androgen deprivation therapy. Despite of tremendous research …

Prostate cancer is the most frequently diagnosed tumor in men and the second most
common cause of cancer-related death for males in the United States. It has been shown …

Prostate cancer (PCa) primarily depends on the dysregulations of androgen receptor (AR)
signaling pathway for the initiation and growth as well as recurrence after chemotherapy [1] …

BACKGROUND Androgens control homeostasis of the normal prostate and growth of
prostate cancer (PCa) through the androgen receptor (AR) by regulating gene networks …

Skp2 is a crucial component of SCFSkp2 E3 ubiquitin ligase and is often overexpressed in
various types of cancer, including prostate cancer (PCa). The epithelial-to-mesenchymal …

Aberrant Skp2 signaling has been implicated as a driving event in tumorigenesis. Although
the underlying molecular mechanisms remain elusive, cytoplasmic Skp2 correlates with …

Substantial evidence supports the oncogenic role of the E3 ubiquitin ligase S-phase kinase-
associated protein 2 (Skp2) in many types of cancers through its ability to target a broad …

Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …

Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However,
80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent …